Contrast-enhanced magnetic resonance angiography in rabbits: Evaluation of the gadolinium-based agent P846 and the iron-based blood pool agent P904 in comparison with gadoterate meglumine

Investigative Radiology

Volumn 46, Issue 8, 2011, Pages 524-529

  Kinner, Sonja ^a   Maderwald, Stefan ^a,b   Parohl, Nina ^a   Albert, Juliane ^a   Corot, Claire ^c   Robert, Philippe ^c   Barkhausen, Jörg ^a,d   Vogt, Florian M ^a,d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ERWIN L HAHN INSTITUTE FOR MAGNETIC RESONANCE IMAGING   (Germany)

^c Laboratoire Guerbet   (France)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

blood pool; contrast agents; gadolinium; MR angiography; USPIO

Indexed keywords

GADOTERATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; P 846; P 904; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AORTA; ARTICLE; CONTRAST ENHANCEMENT; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; SIGNAL NOISE RATIO;

EID: 79959787126     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31821ae21f     Document Type: Article

References (28)

1. Gozzi M, Amorico MG, Colopi S, et al. Peripheral arterial occlusive disease: role of MR angiography. Radiol Med. 2006;111:225-237.
2. Lim RP, Shapiro M, Wang EY, et al. 3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA. Am J Neuroradiol. 2008;29:1847-1854.
3. Nael K, Fenchel M, Krishnam M, et al. 3.0 Tesla high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) of the pulmonary circulation: initial experience with a 32-channel phased array coil using a high relaxivity contrast agent. Invest Radiol. 2007;42:392-398. (Pubitemid 46788738)
4. Huppertz A, Kroll H, Klessen C, et al. Biphasic blood pool contrast agentenhanced whole-body MR angiography for treatment planning in patients with significant arterial stenosis. Invest Radiol. 2009;44:422-432.
5. Mell M, Tefera G, Thornton F, et al. Clinical utility of time-resolved imaging of contrast kinetics (TRICKS) magnetic resonance angiography for infrageniculate arterial occlusive disease. J Vasc Surg. 2007;45:543-548; discussion 548. (Pubitemid 46281530)
6. Voth M, Haneder S, Huck K, et al. Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/ kg) of gadobutrol at 3.0 T. Invest Radiol. 2009;44:627-633.
7. Casneuf VF, Delrue L, van Damme N, et al. Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. Radiat Res. 2011;175:10-20.
8. Fries P, Runge VM, Bucker A, et al. Brain tumor enhancement in magnetic resonance imaging at 3 Tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular Gd-chelate in a rat brain tumor model. Invest Radiol. 2009;44:200-206.
9. Peldschus K, Hamdorf M, Robert P, et al. Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadolinium-based contrast agent P846 in comparison with gadoterate meglumine in rabbits at 1.5 Tesla and 3.0 Tesla. Invest Radiol. 2008;43:837-842.
10. Heilmann M, Vautier J, Robert P, et al. In vitro setup to study permeability characteristics of contrast agents by MRI. Contrast Media Mol Imaging. 2009;4:66-72.
11. Sigovan M, Bessaad A, Alsaid H, et al. Assessment of age modulated vascular inflammation in ApoE-/- mice by USPIO-enhanced magnetic resonance imaging. Invest Radiol. 2010;45:702-707.
12. Sigovan M, Boussel L, Sulaiman A, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology. 2009;252:401-409.
13. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. (Pubitemid 41546838)
14. Corot C, Port M, Guilbert ISuperparamagnetic contrast agents.In: Modo MJ, Bulte JW, eds. Molecular and Cellular MR Imaging. Boca Raton, FL: CRC Press; 2007:59-83.
15. Song T, Laine AF, Chen Q, et al. Optimal k-space sampling for dynamic contrast-enhanced MRI with an application to MR renography. Magn Reson Med. 2009;61:1242-1248.
16. Dietrich O, Raya JG, Reeder SB, et al. Measurement of signal-to-noise ratios in MR images: influence of multichannel coils, parallel imaging, and reconstruction filters. J Magn Reson Imaging. 2007;26:375-385. (Pubitemid 47257737)
17. Corot C, Violas X, Robert P, et al. Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol. Invest Radiol. 2003;38:311-319. (Pubitemid 36627248)
18. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. Eur Radiol. 2007;17:3017-3024. (Pubitemid 350142325)
19. Allkemper T, Bremer C, Matuszewski L, et al. Contrast-enhanced bloodpool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology. 2002;223:432-438. (Pubitemid 34454322)
20. Goyen M, Shamsi K, Schoenberg SO. Vasovist-enhanced MR angiography. Eur Radiol. 2006;16(Suppl 2):B9-B14.
21. Michaely HJ, Attenberger UI, Dietrich O, et al. Feasibility of gadofosvesetenhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation. Invest Radiol. 2008;43:635-641.
22. Hadizadeh DR, Gieseke J, Lohmaier SH, et al. Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standardresolution first-pass MR angiography and DSA. Radiology. 2008;249:701-711.
23. Prince MR, Zhang HL, Prowda JC, et al. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics. 2009;29:1565-1574.
24. Jacquier A, Wendland M, Do L, et al. MR imaging assessment of the kinetics of P846, a new gadolinium-based MR contrast medium, in is chemically injured myocardium. Contrast Media Mol Imaging. 2008;3:112-119.
25. Jacquier A, Bucknor M, Do L, et al. P846, a new gadolinium based low diffusion magnetic resonance contrast agent, in characterizing occlusive infarcts, reperfused ischemic myocardium and re-perfused infarcts in rats. MAGMA. 2008;21:207-218.
26. Taupitz M, Schnorr J, Abramjuk C, et al. New generation of monomerstabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Magn Reson Imaging. 2000;12:905-911.
27. Tombach B, Reimer P, Bremer C, et al. First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed. 2004;17:500-506. (Pubitemid 39549427)
28. Seng K, Maderwald S, de Greiff A, et al. Dynamic contrast-enhanced magnetic resonance angiography of the thoracic vessels: an intraindividual comparison of different k-space acquisition strategies. Invest Radiol. 2010; 45:708-714.